期刊文献+

罗格列酮对高糖刺激下新生大鼠心脏成纤维细胞胶原表达的调节 被引量:1

Effect of rosiglitazone on high glucose-induced collagen synthesis expression of neonatal rat cardiac fibroblast
原文传递
导出
摘要 目的:离体条件下葡萄糖孵育SD大鼠乳鼠心脏成纤维细胞,观察罗格列酮干预后,对乳鼠心脏成纤维细胞表达Ⅰ型前胶原的影响,从而探讨罗格列酮在糖尿病心肌病心肌纤维化中的作用机制。方法:提取、培养新生SD大鼠心脏成纤维细胞,设对照组(葡萄糖5.5mmol.L-1);低糖5.5mmol.L-1+罗格列酮组;高糖30mmol.L-1组;高糖30mmol.L-1+罗格列酮组。应用Real time PCR法测定心脏成纤维细胞Ⅰ型前胶原-mRNA表达;Western blot检测Ⅰ型前胶原蛋白质的表达。结果:罗格列酮对高糖孵育下心脏成纤维细胞Ⅰ型前胶原-mRNA/protein表达的影响:与对照组相比,高糖刺激下Ⅰ型前胶原-mRNA/protein表达均增加(P<0.01)。与高糖30mmol.L-1组相比,高糖30mmol.L-1+罗格列酮组Ⅰ型前胶原-mRNA/protein表达降低(P<0.05)。结论:罗格列酮抑制了高血糖环境内心脏成纤维细胞胶原的合成,可能在抑制心肌纤维化的过程中发挥了作用。 OBJECTIVE To observe the impact of rosiglitazone on collagen I synthesis expression in neonatal rat cardiac fi- broblast cell, and to explore the mechanism of action of rosiglitazone in myocardial fibrosis of diabetes cardio-myopathy. METHODS SD neonatal rat cardiac fibroblasts were incubated in vitro and after the intervention of rosiglitazone. Neonatal SD rat cardiac fibroblasts were extracted and cultured.. (1)control group (normal glucose 5. 5 mmol.L-1 ), (2)high glucose(30 mmol. L-1 ), (3) low glucose (5. 5 mmol L- 1 ) and rosiglitazone, (4) high glucose (30 mmol L- 1 ) and rosiglitazone. Real time PCR was used to detect the expression of precollagen I mRNA of neonatal rat cardiac fibroblasts and Western blot was used to detect protein of precollagen I. RESULTS The influence of precollagen I -mRNA/protein under high glucose (30 rnmol. L- t ) by ros- iglitazone: compared to the control group, the expression of precollagen I-mRNA/protein in high glucose 30 mmol.L-1 was increased. There was statistically significant differences(P〈0. 01). Moreover, precollagen I-mRNA/protein expression in high glucose 30 mmol-L-1 + rosiglitazone group was significantly lower than high glucose 30 mmol. L-1 group. The difference was significant (P〈0. 05). CONCLUSION Rosiglitazone inhibits the expression of collagen secretion rat cardiac fibroblasts in the environment of hyperglycemia, which maybe plays a role in the process of inhibition of myocardial fibrosis.
出处 《中国医院药学杂志》 CAS CSCD 北大核心 2013年第9期703-706,共4页 Chinese Journal of Hospital Pharmacy
关键词 心脏成纤维细胞 高葡萄糖 胶原 罗格列酮 cardiac fibroblasts high glucose collagen rosiglitazone
  • 相关文献

参考文献6

二级参考文献44

  • 1赵全明,颜东,宋爱丽,王伟,时强,王绿娅,陈冬,方薇,武迎,许金鹏,陈欣,陈铁军,米树华,吕树铮.罗格列酮对ApoE基因敲除小鼠动脉粥样硬化的影响[J].中华心血管病杂志,2005,33(5):399-404. 被引量:15
  • 2袁晓晨,刘乃丰,张昕.吡格列酮和厄贝沙坦对糖基化终产物诱导血管平滑肌细胞增殖的影响[J].中国新药与临床杂志,2006,25(7):501-504. 被引量:6
  • 3魏丽,贾伟平,吴海娅,陆俊茜,包玉倩,陆惠娟,潘晓平,项坤三.肥胖及2型糖尿病患者血清apelin水平及其相关因素分析[J].中华内分泌代谢杂志,2007,23(2):130-133. 被引量:39
  • 4LIBBY P,PLUTZKY J. Inflammation in diabetes mellitus: role of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated peceptor-gamma agonists[J]. Am J Cardiol, 2007, 99(4A): 27B-40B.
  • 5SUNG B, PARK S, YU BP, et al. Amelioration of age-related inflammation and oxidative stress by PPARγ activator: suppression of NF-κB by 2,4-thiazolidinedione[J]. Exp Gerontol, 2006, 41(6) : 590-599.
  • 6GAO DF, NIU XL, HAO GH, et al. Rosiglitazone inhibits angiotensin Ⅱ-induced CTGF expression in vascular smooth muscle cells-role of PPAR-gamma in vascular fibrosis [J]. Biochem Pharmacol, 2007, 73(2): 185-197.
  • 7NEUSCHWANDER-TETRI BA, BRUNT EM, WEHMEIER KR, et al. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gammar ligand rosiglitazone[J]. Hepatology, 2003, 38(4): 1008-1017.
  • 8PERBAL B. CCN proteins: multifunctional signaling regulators [J]. Lancet, 2004, 363(9402): 62-64.
  • 9郭晓珍,任利群,刘乃丰.罗格列酮对血管平滑肌细胞血管紧张肽Ⅱ受体2表达的影响[J].中国新药与临床杂志,2007,26(7):508-512. 被引量:3
  • 10Chen MP,Chung FM,Chang DM,et al.Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus[J].J Clin Endocrinol Metab,2006,91(1):295-299.

共引文献45

同被引文献16

  • 1NICHOLS G A, HILLIER T A, ERBEY J R, et al. Conges- tive heart failure in type 2 diabetes--prevalence, incidence, and risk factors[J]. Diabetes Care, 2001,24(9) : 1614-1619.
  • 2MIZUSHIGE K, YAO L, NOMA T, et al. Alteration in left ventricular diastolic filling and accumulation of myocardial col- lagen at insulin-resistant prediabetic stage of a type II diabetic rat model[J]. Circulation, 2000,101 (8) : 899-907.
  • 3ROSS B, MCKENDY K, GIAID A. Role of urotensin ]l in health and disease[J]. American Journal of Physiology-Regula- tory Integrative and Comparative Physiology, 2010,298 (5): Rl156-R1172.
  • 4TZANIDIS A, HANNAN R D, THOMAS W G, et al. Direc- tactions of urotensin [I on the heart., implications for cardiac fibrosis and hypertrophy[J]. Circulation Research, 2003, 93 (3) :246-253.
  • 5BOUSETTE N, HU F, OHLSTEIN E H, et al. Urotensin-II blockade with SB-611812 attenuates cardiac dysfunction in a rat model of coronary artery ligation[J]. Journal of Molecular and Cellular Cardiology, 2006,41(2) ;285-295.
  • 6LANGHAM R G, KELLY D J, GOW R M, et al. Increased expression of urotensin 1][ and urotensin n receptor in human diabetic nephropathy[J]. American Journal of Kidney Disea- ses: the Official Journal of the National Kidney Foundation, 2004,44(5) : 826-831.
  • 7TIAN L, LI C, QI J P, et al. Diabetes-induced upregulation of urotensin II and its receptor plays an important role in TGF- betal-mediated renal fibrosis and dysfunction [J]. American Journal of Physiology-Endocrinology and Metabolism, 2008, 295(5) : E1234-E1242.
  • 8CLOZEL M, HESS P, QIU C B, et al. The urotensin-H re- cePtor antagonist palosuran improves pancreatic and renal function in diabetic rats[J]. The Journal of Pharmacology and Experimental Therapeutics, 2006,316(3) :1115-1121.
  • 9DAI H Y, GUO X G, GE Z M, et al. Elevated expression of urotensin and its receptor in diabetic cardiomyopathy[J]. Journal of Diabetes and Its Complications, 2008,22 (2):137- 143.
  • 10DOAN N D, NGUYEN T, LETOURNEAU M, et al. Bio- chemical and pharmacological characterization of nuclear uro- tensin- 1I binding Sites in rat heart[J]. British Journal of Phar- macology, 2012,166(1, SI) :243-257.

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部